{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:54:11Z","timestamp":1787612051995,"version":"build-2736575974"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Antimicrob. Chemother."],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1093\/jac\/dkw298","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T20:48:57Z","timestamp":1470430137000},"page":"3008-3019","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality"],"prefix":"10.1093","volume":"71","author":[{"given":"William","family":"Hope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Rex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"2016102607352759000_71.11.3008.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02913.x"},{"key":"2016102607352759000_71.11.3008.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00018-3"},{"key":"2016102607352759000_71.11.3008.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.02.004"},{"key":"2016102607352759000_71.11.3008.4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3487-3496.2001"},{"key":"2016102607352759000_71.11.3008.5","doi-asserted-by":"publisher","DOI":"10.1086\/515033"},{"key":"2016102607352759000_71.11.3008.6","doi-asserted-by":"publisher","DOI":"10.1086\/514341"},{"key":"2016102607352759000_71.11.3008.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04723-14"},{"key":"2016102607352759000_71.11.3008.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro862"},{"key":"2016102607352759000_71.11.3008.9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00601-06"},{"key":"2016102607352759000_71.11.3008.10","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1128\/AAC.42.11.2898","article-title":"Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits","volume":"42","author":"Petraitis","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01387-12"},{"key":"2016102607352759000_71.11.3008.12","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S1201-9712(08)60122-8","article-title":"(1\u21923)-\u03b2-d-Glucan in cerebrospinal fluid is a surrogate marker for detection and therapeutic response of hematogenous Candida meningoencephalitis","volume":"12","author":"Petraitiene","year":"2008","journal-title":"Int J Infect Dis"},{"key":"2016102607352759000_71.11.3008.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01750-10"},{"key":"2016102607352759000_71.11.3008.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ817"},{"key":"2016102607352759000_71.11.3008.15","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.42.5.1105","article-title":"Pharmacodynamics of fluconazole in a murine model of systemic candidiasis","volume":"42","author":"Louie","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01083-10"},{"key":"2016102607352759000_71.11.3008.17","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.10.3165-3169.2003"},{"key":"2016102607352759000_71.11.3008.19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"2016102607352759000_71.11.3008.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5058-5068.2005"},{"key":"2016102607352759000_71.11.3008.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1187-1192.2003"},{"key":"2016102607352759000_71.11.3008.22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00478-08"},{"key":"2016102607352759000_71.11.3008.23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00621-11"},{"key":"2016102607352759000_71.11.3008.24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01337-06"},{"key":"2016102607352759000_71.11.3008.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01686-10"},{"key":"2016102607352759000_71.11.3008.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06369-11"},{"key":"2016102607352759000_71.11.3008.27","doi-asserted-by":"publisher","DOI":"10.1086\/524063"},{"key":"2016102607352759000_71.11.3008.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05826-11"},{"key":"2016102607352759000_71.11.3008.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.938-942.2000"},{"key":"2016102607352759000_71.11.3008.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00369-06"},{"key":"2016102607352759000_71.11.3008.31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00787-06"},{"key":"2016102607352759000_71.11.3008.32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1908-1911.2004"},{"key":"2016102607352759000_71.11.3008.33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00673-10"},{"key":"2016102607352759000_71.11.3008.34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01355-13"},{"key":"2016102607352759000_71.11.3008.35","doi-asserted-by":"publisher","DOI":"10.1086\/510535"},{"key":"2016102607352759000_71.11.3008.36","doi-asserted-by":"publisher","DOI":"10.1086\/424465"},{"key":"2016102607352759000_71.11.3008.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70238-3"},{"key":"2016102607352759000_71.11.3008.38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00980-12"},{"key":"2016102607352759000_71.11.3008.39","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01430-12"},{"key":"2016102607352759000_71.11.3008.40","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis372"},{"key":"2016102607352759000_71.11.3008.41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00662-11"},{"key":"2016102607352759000_71.11.3008.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.469-473.2006"},{"key":"2016102607352759000_71.11.3008.43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04907-14"},{"key":"2016102607352759000_71.11.3008.44","unstructured":"Hope WW , Livermore J , Goodwin J et al . Pharmacokinetics and pharmacodynamics (PK-PD) of F901318 against Aspergillus fumigatus . In: Abstracts of the Fifty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 2015. Abstract M-394. American Society for Microbiology, Washington, DC, USA."},{"key":"2016102607352759000_71.11.3008.45","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"},{"key":"2016102607352759000_71.11.3008.46","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01279-12"},{"key":"2016102607352759000_71.11.3008.47","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"2016102607352759000_71.11.3008.48","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12148"},{"key":"2016102607352759000_71.11.3008.49","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/AAC.01364-15","article-title":"Pharmacodynamics of isavuconazole in a dynamic in vitro model of invasive pulmonary aspergillosis","volume":"60","author":"Box","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit164"},{"key":"2016102607352759000_71.11.3008.51","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00216-13"},{"key":"2016102607352759000_71.11.3008.52","doi-asserted-by":"crossref","first-page":"e00725","DOI":"10.1128\/mBio.00725-13","article-title":"Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days","volume":"5","author":"Livermore","year":"2014","journal-title":"MBio"},{"key":"2016102607352759000_71.11.3008.53","first-page":"177","article-title":"Chronic cryptococcal meningitis: a new experimental model in rabbits","volume":"101","author":"Perfect","year":"1980","journal-title":"Am J Pathol"},{"key":"2016102607352759000_71.11.3008.54","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1128\/AAC.40.9.2178","article-title":"Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis","volume":"40","author":"Larsen","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.55","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3297-3301.2005"},{"key":"2016102607352759000_71.11.3008.56","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/AAC.41.7.1589","article-title":"Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis","volume":"41","author":"Thomas","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2016102607352759000_71.11.3008.57","unstructured":"FDA. Drugs Intended to Treat Life-Threatening and Severely Debilitating Illnesses . http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:501135 ."},{"key":"2016102607352759000_71.11.3008.58","unstructured":"EMA. Pilot Project on Adaptive Licensing . 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2014\/03\/WC500163409.pdf ."},{"key":"2016102607352759000_71.11.3008.59","unstructured":"FDA. Guidance for Industry: Expedited Programs for Serious Conditions\u2014Drugs and Biologics . 2014. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm358301.pdf ."},{"key":"2016102607352759000_71.11.3008.60","unstructured":"EMA. Guideline on the Clinical Evaluation of Antifungal Agents for the Treatment and Prophylaxis of Invasive Fungal Disease . 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/05\/WC500090118.pdf ."},{"key":"2016102607352759000_71.11.3008.61","unstructured":"EMA. Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections . 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf ."},{"key":"2016102607352759000_71.11.3008.62","unstructured":"EMA. Guideline on the Use of Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products . 2015. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/09\/WC500194333.pdf ."},{"key":"2016102607352759000_71.11.3008.63","unstructured":"Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts\u2014Third Edition: Approved Standard M27-A3 . CLSI, Wayne, PA, USA, 2008."},{"key":"2016102607352759000_71.11.3008.64","unstructured":"Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi\u2014Second Edition: Approved Standard M38-A2 . CLSI, Wayne, PA, USA, 2008."},{"key":"2016102607352759000_71.11.3008.65","unstructured":"EUCAST. EUCAST Definitive Document E.DEF 9.3: Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds . http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/AFST\/Files\/EUCAST_E_Def_9_3_Mould_testing_definitive.pdf ."},{"key":"2016102607352759000_71.11.3008.66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03880.x"},{"key":"2016102607352759000_71.11.3008.67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"2016102607352759000_71.11.3008.68","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.794785"},{"key":"2016102607352759000_71.11.3008.69","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-13"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/71\/11\/3008\/7941193\/dkw298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T03:32:08Z","timestamp":1568259128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkw298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":69,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,10,21]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1093\/jac\/dkw298"],"URL":"https:\/\/doi.org\/10.1093\/jac\/dkw298","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}